Status:
TERMINATED
Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on Periodontium
Lead Sponsor:
Nantes University Hospital
Conditions:
Rheumatoid Arthritis
Periodontitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Rheumatoid arthritis and periodontitis are two inflammatory diseases that share many pathophysiological similarities as some inflammatory mediators like TNF-alpha, IL-1, Il-6, Il-17, Il-12 et Il-17, R...
Eligibility Criteria
Inclusion
- patient over 18 years presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is prescribed.
- At least 18 permanent teeth in the mouth at least 3 teeth with a healthy periodontal status
- Having expressed their written free and informed consent
Exclusion
- Hypersensitivity to any of the following components : tocilizumab, saccharose, polysorbate 80, phosphate disodique dodécahydrate, phosphate monosodique dehydrate
- Severe or active infections
- Systemic Pathology affecting the immune system including Sjögren's syndrome
- Surgery in the previous month
- HIV positive
- Alcoholic
- Toxicoman
- Antibiotic treatment in the last 2 months
- Legally protected patients
Key Trial Info
Start Date :
December 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01806974
Start Date
December 1 2012
End Date
June 1 2015
Last Update
November 3 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Brest University Hospital
Brest, France
2
Nantes University Hospital
Nantes, France